Is BEAM or BIVI more undervalued in 2026?

CirclFi compares Beam Therapeutics Inc. (BEAM) and BioVie Inc. (BIVI) using 13 institutional-grade valuation models. BEAM has a Quality of Company score of 6.4/10 while BIVI scores 3.2/10.

Which is a better buy — BEAM or BIVI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BEAM and BIVI valuations compare?

BEAM at $32.80 and BIVI at $1.44 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BEAM vs BIVI Valuation Comparison 2026 — Intrinsic Value Analysis

BEAM

Biotechnology

Beam Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$32.80

Last close

Models

12/13

Active

BIVI

Biotechnology

BioVie Inc.

Quality

3.2

out of 10

Value Trap

LOW

Price

$1.44

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	BEAM Fair Value	BEAM Upside	BIVI Fair Value	BIVI Upside
Bayesian DCF	Intrinsic	$10.45	-68.1%	$1.46	+1.2%
Earnings Power Value	Intrinsic	$15.21	-43.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$4.51	-83.7%	$0.27	-84.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BEAM vs BIVI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BEAM vs BIVI — Which Stock Is More Undervalued?

BEAM scores higher with a 6.4/10 quality rating vs BIVI's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Beam Therapeutics Inc. (BEAM) and BioVie Inc. (BIVI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BEAM currently trades at $32.80 with a QOC of 6.4/10, while BIVI trades at $1.44 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).